https://pharmasource.global/content/news/cdmo-news/piramal-pharma-solutions-partners-with-ajinomoto-to-expand-adc-manufacturing-capabilities/
Piramal Pharma Solutions Partners with Ajinomoto to Expand ADC Manufacturing Capabilities -...
Apr 17, 2026 - Piramal Pharma Solutions has announced a strategic collaboration with Ajinomoto Bio-Pharma Services to expand capabilities in antibody-drug conjugate (ADC)...
piramal pharmasolutions partnersadc manufacturing
https://www.sigmaaldrich.com/CH/it/applications/pharmaceutical-and-biopharmaceutical-manufacturing/adc-manufacturing/conjugation
ADC Manufacturing: Coniugazione
La fase di coniugazione nella produzione di ADC consiste nell'attaccare un principio attivo farmaceutico altamente potente (HPAPI) a un mAb tramite un linker...
adc manufacturing
https://www.piramalpharmasolutions.com/antibody-drug-conjugates
Antibody Drug Conjugate Services | ADC Manufacturing & Bioconjugation
Piramal Pharma Solutions delivers standalone and integrated Antibody Drug Conjugate (ADC) and bioconjugation services, spanning early conjugation development...
antibody drug conjugateadc manufacturingservicesbioconjugation
https://www.pharmamanufacturing.com/sector/large-molecule/news/33000467/astrazeneca-bets-on-cancer-adc
AstraZeneca bets on cancer ADC | Pharma Manufacturing
The drugmaker could pay up to $1.1B for KYM Biosciences' promising gastric cancer therapy
astrazenecabetscanceradcpharma